ASH21

BeyondSpring Inc (NASDAQ: BYSI) announced new data highlighting the mechanism of action of plinabulin in preventing chemotherapy-induced neutropenia (CIN) at the American Society of Hematology (ASH) Annual Meeting and Exposition.  The comparison was made between cancer patients...

Global Blood Therapeutics Inc (NASDAQ: GBT) priced $300 million Convertible Senior Notes due 2028 in a private offering.  The offering size was increased from the previously announced offering size of $250 million.  Initial purchasers have an option to purchase up to an...

Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen R-CHOP. Data were presented at the American Society of Hematology (ASH) Annual Meeting and Exposition. Polivy...

Sanofi SA (NASDAQ: SNY) presented data from two Phase 3 studies of fitusiran for the prophylactic treatment with hemophilia A or B, with or without inhibitors. Data were shared at the American Society of Hematology (ASH) Annual Meeting.  Fitusiran, an RNAi drug designed to...

Agios Pharmaceuticals Inc (NASDAQ: AGIO) reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat in adults with pyruvate kinase (PK) deficiency. Data were featured at the American Society of Hematology (ASH) Annual Meeting and...

Precigen Inc (NASDAQ: PGEN) presented positive interim data at the ASH Annual Meeting and Exposition from the ongoing Phase 1/1b study of PRGN-3006 UltraCAR-T in relapsed or refractory (r/r) acute myeloid leukemia and higher-risk myelodysplastic syndromes. PRGN-3006 UltraCAR-T is a...

Atara Biotherapeutics Inc (NASDAQ: ATRA) posted efficacy and safety results from its Phase 3 ALLELE study of tabelecleucel (tab-cel) for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). EBV+ PTLD is a rare complication after a solid organ (SOT) or...

Aptose Biosciences Inc (NASDAQ: APTO) presented data from the ongoing Phase 1/2 study of HM43239 in patients relapsed or refractory acute myeloid leukemia (AML) who had received at least one prior line of therapy. Data were presented at the American Society of Hematology (ASH)...

Fate Therapeutics Inc (NASDAQ: FATE) showcased interim Phase 1 data from its FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the American Society of Hematology (ASH) Annual Meeting and Exposition.  In the second, third, and fourth dose cohorts of...

Kite Pharma, a Gilead Science Inc company (NASDAQ: GILD), churned out more data for its CAR-T Yescarta in first-line lymphoma patients.  The Company shared the data at the American Society of Hematology (ASH) Annual Meeting & Exposition. In updated results from the...

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed-lineage leukemia rearranged (MLLr) relapsed/refractory acute leukemias. The data were...

ALX Oncology Holdings Inc (NASDAQ: ALXO) presented initial clinical data from its ongoing Phase 1 / 2 trial evaluating evorpacept combined with azacitidine for untreated higher-risk or relapsed or refractory myelodysplastic syndrome.  The new results were shared at the 63rd...

X4 Pharmaceuticals Inc (NASDAQ: XFOR) shares are trading lower despite releasing what it described as positive phase 2 data for mavorixafor for WHIM syndrome, a rare congenital immune deficiency. In a poster presentation at the American Society of Hematology Annual Meeting,...

Viracta Therapeutics Inc (NASDAQ: VIRX) announced final data from its Phase 1b/2 trial of Nana-val in relapsed/refractory (R/R) EBV+ lymphoma. The data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting. Nana-val was well tolerated and demonstrated...

Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at the American Society of Hematology (ASH) 2021 Annual Meeting. With approvals already in place as triplet therapies,...